Moreover, methylation of FAM19A4 has been proposed as an alternative biomarker for early detection of cervical cancer, particularly high-grade squamous intraepithelial lesions (HSIL) [10, 19], as well as a new triage tool for self-sample collection [20] in hrHPV-positive women. This evidence concerns the gene TAFA4 and cervical cancer.